Dianthus Therapeutics (DNTH) Total Non-Current Liabilities (2018)
Dianthus Therapeutics (DNTH) posted quarterly Total Non-Current Liabilities of $1.2 million for Q4 2018, up 15.37% quarter-over-quarter from $1.1 million in Q3 2018.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Total Non-Current Liabilities (2018) Analysis & Trends
Dianthus Therapeutics' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $1.2 million for Q4 2018.
- In Q4 2018, Total Non-Current Liabilities changed N/A year-over-year to $1.2 million; the TTM figure through Dec 2018 stood at $1.2 million (changed N/A YoY), while the FY2018 annual figure was $1.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2018 stood at $1.2 million, up from $1.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.2 million in Q4 2018, with the low at $796000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 1.25 Mn |
| Sep 30, 2018 | 1.08 Mn |
| Jun 30, 2018 | 796,000.00 |